Arcutis Biotherapeutics, Inc.

Good day and thank you for standing by. Welcome to the Arcudis Biotherapeutics 2025 Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Brian Sholkoff, Head of Investor Relations. Please go ahead.

Thank you, Michelle. Good afternoon, everyone, and thank you for joining us today to review our second quarter 2025 Financial Results and Business Update. Slides for today's call are available on the Investors section of the Arcudis website. On the call today are Frank Watanabe, President and CEO, Patrick Burnett, Chief Medical Officer, Todd Edwards, Chief Commercial Officer, and Latha Viravan, Chief Financial Officer. I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand the call over to Frank.

Thanks, Brian, and thank you to everyone for joining us today. I'm pleased to report that in the second quarter, we continue to see strong sales and demand growth with our Zureve franchise, demonstrating continued adoption by healthcare providers and patients, and consistent execution by our commercial team. During today's call, we will review in detail the results for the quarter, but we'll also spend time talking in more depth about our plans to sustain our growth into the future, including the next wave of growth for Zureve, how we intend to leverage our -in-class development and commercialization capabilities to address the unmet urgent needs of patients living with immune-mediated dermatologic diseases, and our capital allocation framework to enable this next growth phase. Before I dive in, I wanna thank the exceptional team at Arcutus that is dedicated to and instrumental in advancing our efforts to serve the needs of people living with serious skin diseases. So on slide five, honing in on the second quarter, we saw another quarter of strong revenue growth as patients and clinicians continue to adopt Zureve for the treatment of a range of inflammatory dermatosis. For the quarter, we reported net product revenues of 81.5 million, representing 28% -in-quarter growth and 164% growth compared to the same quarter 2024.